You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma (Skin), Melanoma, Uveal Trial in Oxford (Tebentafusp)

Recruiting
  • Melanoma (Skin)
  • Melanoma, Uveal
  • Oxford, United Kingdom
    Churchill Hospital, Oxford University Hospitals NHS Trust
Jul 28, 2022

T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)

Recruiting
  • T-lymphoblastic Lymphoma
  • +5 more
  • BCL2 Inhibitor plus IM2 regimen
  • Shanghai, Shanghai, China
    Shanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2022

Extramedullary Myeloma Trial in Melbourne (Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent)

Not yet recruiting
  • Extramedullary Myeloma
  • Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Dec 18, 2022

Relapsed or Resistant Acute Leukaemias Trial in Australia, Taiwan (LBS-007)

Not yet recruiting
  • Relapsed or Resistant Acute Leukaemias
  • Adelaide, Australia
  • +3 more
Feb 23, 2023

Hodgkin Lymphoma Trial in Salt Lake City (Axatilimab, Nivolumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Feb 1, 2023

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    National Research Center for Hematology
Dec 13, 2022

Amyloid, Amyloidosis, AL Amyloidosis Trial in New York (Selinexor, Dexamethasone)

Suspended
  • Amyloid
  • +2 more
  • New York, New York
    Weill Cornell Medicine - Multiple Myeloma Center
May 17, 2022

Graves Disease Trial in Hong Kong (Echopulse)

Completed
  • Graves Disease
  • Echopulse
  • Hong Kong, Hong Kong
    Queen Mary Hospital
May 17, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
Oct 31, 2022

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

Recruiting
  • Large B-cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Comprehensive Ablative Bridging Irradiation (CABI)
  • Chimeric Antigen Receptor T-Cell Therapy
  • Tampa, Florida
    Moffitt Cancer Center
Oct 26, 2023

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease Trial (Venetoclax, Decitabine,

Not yet recruiting
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Venetoclax, Decitabine, Azacytidine, Cytarabine
  • (no location specified)
May 4, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Smoking Cessation, Coronary Artery Disease Trial in Ottawa (Cytisine, Nicoderm C-Q Transdermal Product, Nicorette Lozenge

Recruiting
  • Smoking Cessation
  • Coronary Artery Disease
  • Ottawa, Ontario, Canada
    University of Ottawa Heart Insitute - Prevention and Wellness Ce
Apr 29, 2022

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Relapsed/Refractory Multiple Myeloma Trial in Japan (ABBV-383)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Kashiwa-shi, Chiba, Japan
  • +5 more
Jan 25, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Pembrolizumab plus Chemotherapy (ICE or DHAP))

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab plus Chemotherapy (ICE or DHAP)
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

Recruiting
  • Relapsed/Refractory Classical Hodgkin Lymphoma
  • Brentuximab vedotin
  • Goyang, Gyeonggi-do, Korea, Republic of
    Hyeon-Seok Eom
Feb 12, 2022